Biohybrid

Longxue Guan, Qinxiao Sun, Hancheng Jiang, Dandan Liang, Shiqi Zhang, Laili Huang, Xingang Guan, Xiuli Hu, Guofu Chen

Abstract read

In one paragraph

Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Longxue GuanThe First People's Hospital of Wenling (Taizhou University Affiliated Wenling Hospital), School of Medicine, Taizhou University, Taizhou, 317500, China.

Qinxiao SunCollege of Medical Technology, Beihua University, Jilin, 132013, China.

Hancheng JiangInstitute of Polymer Science and Engineering, School of Chemical Engineering, Hebei University of Technology, Tianjin, 300130, China.

Dandan LiangCollege of Medical Technology, Beihua University, Jilin, 132013, China.

Shiqi ZhangCollege of Medical Technology, Beihua University, Jilin, 132013, China.

Laili HuangCollege of Medical Technology, Beihua University, Jilin, 132013, China.

Xingang GuanThe First People's Hospital of Wenling (Taizhou University Affiliated Wenling Hospital), School of Medicine, Taizhou University, Taizhou, 317500, China.

Xiuli HuInstitute of Polymer Science and Engineering, School of Chemical Engineering, Hebei University of Technology, Tianjin, 300130, China.

Guofu ChenThe First People's Hospital of Wenling (Taizhou University Affiliated Wenling Hospital), School of Medicine, Taizhou University, Taizhou, 317500, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemotherapy can substantially enhance the efficacy of cancer immunotherapy; however, the clinical translation of chemoimmunotherapy is frequently hampered by inefficient drug delivery and dose-limiting systemic toxicity. To address these challenges, we engineered a tumor-targeting

Indexed as

Antitumor immunityChemoimmunotherapyDrug deliveryPD-L1 nanobodySalmonella typhimurium

Identifiers

PMID42621362

DOI10.1016/j.mtbio.2026.103550

PMCPMC13487396

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.